AntieAngiotensin type 1 receptor antibodies associated with antibody-mediated rejection in patients without preformed HLA-DonoreSpecific antibody

Transplantation Proceedings

Volumn 46, Issue 10, 2014, Pages 3371-3374

  In, J W ^a   Park, H ^a   Rho, E Y ^a   Shin, S ^a   Park, K U ^a   Park, M H ^a   Song, E Y ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; HLA ANTIBODY; HLA DONOR SPECIFIC ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; HLA ANTIGEN;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; FEMALE; HUMAN; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MALIGNANT HYPERTENSION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; ADVERSE EFFECTS; DONOR; GRAFT REJECTION; IMMUNOLOGY; MIDDLE AGED; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES; FEMALE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; TISSUE DONORS; YOUNG ADULT;

EID: 84926331182     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2014.09.096     Document Type: Article

References (22)

1. Sumitran-Karuppan S, Tyden G, Reinholt F, et al. Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific or endothelial cells. Transpl Immunol 1997;5:321.
2. Sumitran-Holgersson S, Wilczek HE, Holgersson J, et al. Identification of the nonclassical HLA molecules, MICA, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation 2002;74:268.
3. Zou Y, Heinemann FM, Grosse-Wilde H, et al. Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the posttransplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry. Hum Immunol 2006;67:230.
4. Rose ML. Role of MHC and non-MHC antibodies in graft rejection. Curr Opin Organ Transplant 2004;9:16.
5. Praprotnik S, Blank M, Meroni PL, et al. Classification of antiendothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells. Arthritis Rheum 2001;44:1484.
6. Rodriguez-Mahou M, Salcedo M, Fernandez-Cruz E, et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with GSTT1 null genotype as prognostic marker: Longterm follow-up after liver transplantation. Transplantation 2007;83:1126.
7. Aguilera I, Alvarez-Marquez A, Gentil MA, et al. Antiglutathione S transferase T1 antibody-mediated rejection in C4dpositive renal allograft recipients. Nephrol Dial Transplant 2008;23:2393.
8. Jurcevic S, Ainsworth ME, Pomerance A, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001;71:886.
9. Carter V, Shenton BK, Jaques B, et al. Vimentin antibodies: A non-HLA antibody as a potential risk factor in renal transplantation. Transplant Proc 2005;37:654.
10. Dragun D, Muller DN, Brasen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal allograft rejection. N Engl J Med 2005;352:558.
11. Dragun D. Humoral responses directed against non-human leukocyte antigens in solid-organ transplantation. Transplantation 2008;86:1019.
12. Amico P, Honger G, Bielmann D, et al. Incidence and prediction of early antibody-mediated rejection due to non-human leukocyte antigen antibodies. Transplantation 2008;85:1557.
13. Reinsmoen NL, Lai CH, Heidecke H, et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 2010;90:1473.
14. Hunyadi L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 2006;20:953.
15. Fu ML, Herlitz H, Schulze W, et al. Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens 2000;18:945.
16. Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999;103:945.
17. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008;8:753.
18. Scornik JC, Guerra G, Schold JD, et al. Value of posttransplant antibody tests in the evaluation of patients with renal graft dysfunction. Am J Transplant 2007;7:1808.
19. Dragun D. The role of angiotensin II type 1 receptoractivating antibodies in renal allograft vascular rejection. Pediatr Nephrol 2007;22:911.
20. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension 2001;37: 1047.
21. Fu ML, Herlitz H, Wallukat G, et al. Functional autoimmune epitope on a1-adrenergic receptors in patients with malignant hypertension. Lancet 1994;344:1660.
22. Coffman TM, Crowley SD. Kidney in hypertension: Guyton redux. Hypertension 2008;51:811.